US limits Covid-19 boosters to over-65s or those at high risk
US limits Covid-19 boosters to over-65s or those at high risk
WASHINGTON - The United States will limit Covid-19 boosters to people over 65 or those at risk of serious illness, while requiring vaccine makers to run fresh clinical trials before offering shots to younger and healthier individuals, officials said on May 20.
Writing in the New England Journal of Medicine, the Food and Drug Administration's Dr Vinayak Prasad and Commissioner Martin Makary framed the policy shift as 'evidence-based' and would align the United States more closely with guidance in Europe.
But it comes as Health Secretary Robert F. Kennedy Jr, a longtime vaccine sceptic, pushes to remake federal public health policy.
Mr Kennedy previously led a non-profit that was critical of immunisation programs, and during the pandemic petitioned the FDA to revoke Covid-19 vaccine authorisations, citing rare side effects including heart inflammation.
Dr Prasad and Mr Makary praised the initial Covid-19 vaccine rollout as 'a major scientific, medical, and regulatory accomplishment,' but argued that the benefits of repeated boosters for low-risk individuals are uncertain.
They criticised the US approach of recommending boosters for all adults regardless of age or health status, calling it a 'one-size-fits-all' model based on the mistaken belief that Americans couldn't handle more nuanced, risk-based advice.
Rather than building public trust, they wrote, it had backfired – fuelling vaccine hesitancy that has spilled over into scepticism toward childhood shots, including those for measles.
The FDA said it would rely on lab test results to approve boosters for people who are over 65, or over six months old with at least one underlying condition.
But for healthy individuals between six months and 64 years, regulators will now require data from randomised trials.
'We simply don't know whether a healthy 52-year-old woman with a normal BMI (body mass index) who has had Covid-19 three times and has received six previous doses of a Covid-19 vaccine will benefit from the seventh dose,' they wrote.
Some infectious disease experts welcomed the shift.
Dr Amesh Adalja of Johns Hopkins University said it matched with the approach taken by other countries in a population that already carries significant immunity.
'For lower-risk individuals, the goal has always been less clear, as protection against infection is transient and they don't have a high risk of severe disease,' he told AFP.
But others voiced concern about the practical consequences.
Dr Paul Offit, a leading vaccine expert at the Children's Hospital of Philadelphia, said it could limit access for people who still want boosters.
'Any use, say in a healthy 35-year-old, would be considered off-label, and you wonder whether an insurance company would pay for it,' he told AFP.
Not like annual flu shot
Under the revised framework, companies like Pfizer and Moderna will be encouraged to test updated boosters in adults aged 50 to 64.
These studies should measure whether the vaccines reduce symptomatic infections, hospitalizations and deaths.
Rather than comparing new shots to earlier formulations, Dr Prasad and Mr Makary suggested placebo-controlled trials – with saline as the comparator – to better evaluate both benefit and potential side effects.
The proposal, first floated by Mr Kennedy earlier in May, has proved divisive. Critics argue that using a placebo – when authorised vaccines already exist – could expose participants to unnecessary harm.
'Imagine if there was a death or two in the placebo group,' said Dr Offit. 'I don't see how your conscience allow that.'
Supporters of continued Covid-19 boosters often draw parallels to annual flu shots.
But Mr Makary and Dr Prasad pushed back on that comparison, arguing the genetic changes in Covid-19 variants haven't been significant enough to justify automatically updating the vaccine each year.
The FDA officials also sought to reassure Americans concerned they might lose access to boosters under the new framework.
The Centres for Disease Control and Prevention's (CDC) definition of risk factors is 'vast, including obesity and even mental health conditions such as depression,' they wrote, noting that between 100 million and 200 million Americans would likely still qualify. AFP
Join ST's Telegram channel and get the latest breaking news delivered to you.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
a day ago
- Straits Times
Novo Nordisk's Wegovy gets accelerated US approval for serious liver condition
Sign up now: Get ST's newsletters delivered to your inbox The approval makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5 per cent of adults in the US. Novo Nordisk said on Aug 15 that the US Food and Drug Administration has granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH), strengthening its presence in the metabolic disease market. The approval makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5 per cent of adults in the United States, according to the American Liver Foundation. 'There really (have) not been good treatments in this space. We're only the second FDA-approved treatment for MASH, and we really need better medications that have better overall benefit-risk profiles, that really can also prevent the progression of the disease,' Jason Brett, principal US medical head at Novo Nordisk, said in an interview with Reuters. So far, the only available FDA-approved treatment for MASH is the Madrigal Pharmaceuticals drug Rezdiffra, which was approved in 2024. The FDA's decision was based on part one of an ongoing two-part study that showed Wegovy helped improve the organ's condition in more patients with MASH and liver scarring, compared to a placebo. Novo Nordisk said the drug is now available in the United States for adults with MASH and moderate to advanced liver scarring, and is to be used alongside proper diet and exercise. 'MASH patients need access to treatments - and that really can help them, especially early - to prevent it from progressing,' Mr Brett said. 'We're doing as much as we can to work and partner with the payer community around enhancing access and reimbursement.' Top stories Swipe. Select. Stay informed. Singapore 5 new walking trails allow hikers to explore heritage sites, win FairPrice, Cold Storage vouchers World Trump advises Ukraine's Zelensky to 'make a deal' with Russia after meeting Putin World Takeaways: Warm words contrast with cold reality of no deal at Trump-Putin summit Singapore Nowhere to run: Why Singapore needs to start protecting its coasts now Life Switching careers in middle age and beyond: How these Singapore professionals did it Asia 11,000 properties without power after 4.9-magnitude quake strikes near east coast of Australia Asia Move over, Labubu – Chiikawa is the new craze in Hong Kong Life English, physics, chemistry: These tutors take O-level exams every year He did not provide any pricing details. Based on results from part one of the trial, Novo has applied this year for approval in Europe and Japan. Further results from part two of the trial are expected in 2029. Rival Eli Lilly's tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound - previously helped up to 74 per cent of patients achieve absence of MASH with no worsening of scarring in a mid-stage trial. Accelerated approvals allow the FDA to move therapies that target serious and life-threatening conditions to the market more quickly. However, such approvals have been criticised because some drugs have later been proven to be ineffective. REUTERS
Business Times
2 days ago
- Business Times
US: Dow hits record high at open on rate-cut optimism, UnitedHealth boost
[NEW YORK] The blue-chip Dow opened at a record high on Friday (Aug 15), as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake in the health insurer, while expectations of an interest rate cut in September also lifted the mood. The Dow Jones Industrial Average rose 248.7 points, or 0.55 per cent, at the open to 45,159.91. The S&P 500 rose 8.8 points, or 0.14 per cent, at the open to 6,477.38, while the Nasdaq Composite dropped 1.3 points, or 0.01 per cent, to 21,709.336 at the opening bell. REUTERS
Straits Times
2 days ago
- Straits Times
More support for special needs patients as Singapore recognises special care dentistry
Sign up now: Get ST's newsletters delivered to your inbox Cerebral palsy patient Hillary Chua with her mother, Ms Cindy Wong, and Dr Tay Chong Meng, division head of advanced general dental practice at the National University Centre for Oral Health Singapore. SINGAPORE – Born with quadriplegic cerebral palsy, 22-year-old Hillary Chua uses a wheelchair and cannot perform daily functions independently. Her 57-year-old mother, Ms Cindy Wong, has been taking care of her full-time, including diligently cleaning her teeth. Finding a dentist who is trained to treat special needs patients was challenging. Then, during the Covid-19 pandemic, Ms Wong stopped dentist visits altogether because of restrictions. In 2024, she noticed a bad odour from her daughter's mouth. They were referred to the National University Centre for Oral Health Singapore (Nucohs), where Ms Chua was treated by Dr Tay Chong Meng, division head of advanced general dental practice. Dr Tay and his team carefully assessed her needs, as well as the unique challenges posed by her condition, and put together a tailored treatment plan prioritising her safety and comfort. They worked with her mother in providing head support for Ms Chua – who occasionally has sudden head movements due to her lack of muscle control – and trying out various positions to reach her inner teeth, which is challenging as she has difficulty opening her mouth. Dr Tay is among Singapore's growing cohort of special care dentists, an area of specialisation that was officially recognised in July. The Ministry of Health (MOH) announced that the Dental Specialists Accreditation Board (DSAB) will recognise special care dentistry as the eighth dental speciality, joining others such as oral and maxillofacial surgery, orthodontics and paediatric dentistry. 'The new dental speciality addresses the growing need for specialised dental care, particularly in the light of Singapore's ageing population,' MOH had said. Specialists in the field look after the oral healthcare of adults with complex needs, such as those with physical, developmental or cognitive conditions that prevent them from receiving routine dental care. The ministry noted that difficulties in getting appropriate dental care could mean that such individuals face an increased risk of oral diseases, such as dental caries or tooth decay and periodontal disease. This, in turn, could significantly impact their oral function, general health and quality of life, it said. 'The recognition of special care dentistry as a dental speciality will support professional development and encourage more dental practitioners to pursue advanced training in this field,' it added. The DSAB will establish professional standards, as well as enhance training competencies, to ensure dental specialists meet quality care standards. Special care dentistry is also recognised as a speciality in several other countries, such as Australia, Malaysia and Britain. While this field does not have a set of specialised procedures, its practitioners have a better understanding of the relationship between patients' medical condition and their oral health, and are trained in behavioural management. For example, patients with conditions such as autism spectrum disorder or Down syndrome may face anxiety when undergoing dental procedures. 'Careful use of suction, with a lot of reassurance and distraction, will help reduce the anxiety triggered by involuntary salivary flow whenever the mouth is stretched for dental assessment and treatment,' Dr Tay said. Both Nucohs and NDCS have special equipment for those with special needs, such as a wheelchair-tilter, which allows patients with mobility issues to remain in their wheelchairs during treatment. Noting that people with special needs and their caregivers may face difficulty in finding dental practitioners confident in managing challenging cases, Dr Tay said the recognition of the field as a speciality raises awareness that additional help is available for such patients. 'This recognition is also an acknowledgement of the work and efforts by our colleagues to manage the oral health challenges of people with special needs,' he said. Dr Yang Jingrong, who heads the Geriatric and Special Care Dentistry Clinic at the National Dental Centre Singapore (NDCS), said the recognition validates the 'unique skill set and expertise required in treating patients with special needs'. 'This leads to an improved professional identity and better defined scope of practice,' she added. Dr Tay told The Straits Times that visits by special needs patients to Nucohs have been increasing, from about 1,200 in 2022 to about 1,500 in 2023. This could be due to a number of reasons, he said, including greater awareness of the importance of oral health and the extension of government subsidies for special needs outpatients at Nucohs. Dr Tay noted that carrying out simple procedures takes only slightly longer for patients with special needs in most cases. However, there are cases who need a 'significantly longer' time, even taking several visits, depending on the individual. One example is a patient with dental tartar that is significantly bulky or under the gums. 'Then we might need a few visits to build their confidence with under-the gums-scaling,' Dr Tay said, referring to a procedure to remove plaque and tartar build-up below the gum line. He added that the dental team works with caregivers to help introduce patients to a 'realistic and sustainable oral care regime' at home, such as the use of a water pick for those uncomfortable with flossing. Patients can also benefit from targeted dental products that further protect their oral health. 'Improved access to certain therapeutic products, such as high-strength fluoride toothpaste, can allow the caries, or tooth decay, risk to be controlled more appropriately, enhancing the preventive benefits of these products to persons with special healthcare needs,' said Dr Yang. 'Additionally, there can be more education as a whole for caregivers on how to perform oral care for patients with special care needs, as well as modifications to be aware of, such as for persons with swallowing difficulties or with cognitive impairment.' For Ms Wong, the special care services at Nucohs are a major reason why she is willing to take her daughter all the way to the centre in Kent Ridge from their home in Punggol. Aware that her daughter had developed a phobia of doctors after previously undergoing surgery, Dr Tay put her at ease by referring to himself as 'uncle' and being friendly towards her. 'It was the first time I met a doctor who called himself uncle,' said Ms Wong.
